Evidence map›Paper›PMID 38898200›Full record

ArticleNPJ precision oncology2024

Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome.

Dan Zhao, Haiqing Li, Isa Mambetsariev, Tamara Mirzapoiazova, Chen Chen, Jeremy Fricke, Deric Wheeler, Leonidas Arvanitis, Raju Pillai, Michelle Afkhami and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. [Advances in Immunotherapy of KRAS-mutated Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Dan Zhao *Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, USA.ORCID http://orcid.org/0000-0001-7066-9058
Haiqing Li *Integrative Genomic Core, Beckman Research Institute of City of Hope, Duarte, CA, USA.
Isa Mambetsariev *Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, USA.
Tamara MirzapoiazovaDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, USA.
Chen ChenDepartment of Applied AI & Data Science, City of Hope, Duarte, CA, USA.
Jeremy FrickeDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, USA.
Deric WheelerDepartment of Human Oncology, University of Wisconsin, Madison, WI, USA.
Leonidas ArvanitisDepartment of Pathology, City of Hope, Duarte, CA, USA.
Raju PillaiDepartment of Pathology, City of Hope, Duarte, CA, USA.
Michelle AfkhamiDepartment of Pathology, City of Hope, Duarte, CA, USA.
Bihong T ChenDepartment of Diagnostic Radiology, City of Hope, Duarte, CA, USA.
Martin SattlerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Loretta ErhunmwunseeDepartment of Surgery, City of Hope, Duarte, CA, USA.
Erminia MassarelliDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, USA.
Prakash KulkarniDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, USA.
Arya AminiDepartment of Radiation Oncology, City of Hope, Duarte, CA, USA.
Brian ArmstrongLight Microscopy/Digital Imaging Core, City of Hope, Duarte, CA, USA.
Ravi SalgiaDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, USA. rsalgia@coh.org.ORCID http://orcid.org/0000-0001-9643-7626

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI John Charles Williams · 1985 to 2026
$86.3M
Project 2: Targeting Cooperative Phenotypes Common in Spatial HeterogeneityU54CA209978 · NCI · UNIVERSITY OF UTAH · PI MOOS, PHILIP J · 2017 to 2021
$10.5M
Novel approach to attenuate small cell lung cancer growth and metastasisR01CA218545 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI NASSER, MOHD WASIM · 2018 to 2022
$2.6M
NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA218545NCI NIH HHS U54 CA209978U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P30CA033572U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) U54CA209978
6 · The paper itself

Abstract

We conducted spatial immune tumor microenvironment (iTME) profiling using formalin-fixed paraffin-embedded (FFPE) samples of 25 KRAS-mutated non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs), including 12 responders and 13 non-responders. An eleven-marker panel (CD3, CD4, CD8, FOXP3, CD68, arginase-1, CD33, HLA-DR, pan-keratin (PanCK), PD-1, and PD-L1) was used to study the tumor and immune cell compositions. Spatial features at single cell level with cellular neighborhoods and fractal analysis were determined. Spatial features and different subgroups of CD68

Identifiers

PMID38898200
PMCPMC11187132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.